Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Head and Neck Neoplasms 1

Interventions

Cisplatin 144Radiotherapy 71Fluorouracil 50Radiotherapy, Intensity-Modulated 45Docetaxel 39Gemcitabine 38Cetuximab 38Carboplatin 31pembrolizumab 25Capecitabine 22Drug Therapy 17toripalimab 14Paclitaxel 14camrelizumab 10Surgical Procedures, Operative 10Nivolumab 10Chemoradiotherapy 10nimotuzumab 9Radiation 9Neoadjuvant Therapy 8Methotrexate 8Magnetic Resonance Spectroscopy 8Chemotherapy, Adjuvant 8nedaplatin 7Thyrotropin Alfa 7Platinum 7tislelizumab 6spartalizumab 6Standard of Care 6Specimen Handling 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × linrodostat × Head & Neck × Clear all
NCT03386838 2019-04-18

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Bristol-Myers Squibb

Phase 3 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡